On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount DKK    Accumulated until 15 May 2026 131,283 667.28 87,603,049    Monday, 18 May 2026 1,000 676.50 676,500    Tuesday, 19 May 2026 1,000 675.50 675,500    Wednesday, 20 May 2026 1,000 669.00 669,000    Thursday, 21 May 2026 1,000 684.00 684,000    Friday,...

Acquisition expected to deepen Global-e’s standard logistics capabilities and improve the post-purchase experience for merchants and shoppersAcquisition focuses on asset-light carrier capabilities and offering of competitive best in class cross-border, domestic and “last mile delivery” standard logistics, supporting sophisticated solutions such as direct injection, consolidated returns and customs brokerageWill enable expansion of global offering to merchant segments that require a Non-Merchant of Record solution, leveraging the existing Passport platformPETAH-TIKVA, Israel, May 26, 2026 (GLOBE NEWSWIRE) — Global-e Online Ltd. (NASDAQ: GLBE) (“Global-e” or the “Company”), the platform powering global direct-to-consumer e-commerce, today announced that it has entered into a definitive agreement (the “Agreement”) to acquire...

Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products SEATTLE, May 26, 2026 (GLOBE NEWSWIRE) — Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive agreement to be acquired by Lilly. Curevo’s lead product candidate is amezosvatein, an adjuvanted subunit vaccine for the prevention of shingles in adults. While the current standard of care for shingles prevention is effective, tolerability challenges can limit the overall vaccination rates and contribute to second-dose hesitancy, leaving a meaningful portion of patients with reduced or no protection against shingles and its...

TORONTO, May 25, 2026 (GLOBE NEWSWIRE) — G2 Goldfields Inc. (“G2” or the “Company”) (TSX:GTWO; OTCQX:GUYGF) is pleased to announce that it has filed the management information circular (the “Circular”) and related meeting materials (collectively, the “Meeting Materials”) for the special meeting of the holders of common shares of G2 (the “G2 Shareholders”) to be held on June 16, 2026 (the “Meeting”). The mailing of the Meeting Materials to G2 Shareholders has commenced, and the Meeting Materials are also available on the Company’s website at www.g2goldfields.com and under the Company’s profile on SEDAR+ at www.sedarplus.ca. The Arrangement On April 9, 2026, G2 entered into a definitive agreement with G Mining Ventures Corp. (“GMIN”) and G3 Goldfields Inc. (“G3”) pursuant to which GMIN will acquire all of the common shares of G2...

Purchase price of approximately $8.2 million The acquisition represents a continued expansion of PharmaCorp’s footprint in OntarioSASKATOON, Saskatchewan, May 25, 2026 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, today announced that it has entered into a definitive share purchase agreement, dated May 22, 2026 (the “Agreement”) to acquire from an arm’s length vendor group a 100% interest in a PharmaChoice Canada bannered pharmacy located in Morrisburg, Ontario (the “Acquisition”). The Acquisition continues the expansion of the Corporation’s geographical footprint and operating scale. Further to PharmaCorp’s acquisition pipeline update announced in its press release dated April 30,...

Merger Closing Expected to Occur May 28, 2026, Subject to Satisfaction of Closing Conditions OXNARD, Calif., May 22, 2026 (GLOBE NEWSWIRE) — Mission Produce, Inc. (NASDAQ: AVO) (“Mission Produce”) and Calavo Growers, Inc. (NASDAQ: CVGW) (“Calavo”), today announced, in connection with Mission Produce’s pending acquisition of Calavo, that Mission Produce has obtained antitrust clearance from Mexico’s Federal Economic Competition Commission (Comisión Federal de Competencia Económica, or “COFECE”). This clearance satisfies the acquisition’s closing condition set forth in the previously announced merger agreement regarding the receipt of antitrust approval in Mexico. As such, subject to the continued satisfaction of all closing conditions, Mission Produce and Calavo currently expect that the transaction will close on May 28, 2026. About...

LUXEMBOURG, May 22, 2026 (GLOBE NEWSWIRE) — Stoneshield Capital today announced that it has signed an agreement to acquire a 15% stake in Exolum from OMERS, building on its existing investment in the company since January 2026. The remaining 10% of OMERS ~25% stake is separately being acquired by a leading global investment firm with over $100 billion in assets under management. OMERS, together with its investment partners, has been invested in Exolum since 2016. Terms of the transactions are not being disclosed. Exolum is a Spanish-headquartered global energy logistics company specialising in the transportation, storage and distribution of refined products, bulk liquids and aviation fuels, while playing an increasingly important role in supporting the energy transition. Exolum owns a 4,000km transmission pipeline network in Spain...

Ashburn, Virginia, May 22, 2026 (GLOBE NEWSWIRE) — DTC, a Codan company (DTC) and a provider of advanced tactical communications systems, today announced the acquisition of Adaptive Dynamics, Inc., a U.S.-based firm specializing in anti-jamming and interference mitigation technologies for mission-critical communications and Assured Positioning Navigation and Timing.  Adaptive Dynamics brings over two decades of experience in the development of advanced algorithms and RF technologies designed to maintain communications performance in congested and contested electromagnetic environments. Its capabilities include intentional and unintentional interference cancellation, signal enhancement, and adaptive filtering techniques applicable to defense and national security systems.  The acquisition augments DTC’s strategic objective to enhance...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Advanced Medical Solutions Group plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position...

MCLEAN, Va., May 22, 2026 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading provider of AI-driven cybersecurity, IT security solutions, and managed services, today announced the acquisition of Secuvant, LLC (“Secuvant”), a premier provider of enterprise-grade cybersecurity and risk management services. This strategic move dramatically strengthens Cycurion’s MDR, threat and vulnerability management, and compliance capabilities — delivering immediate firepower for mid-market and enterprise clients in construction, agriculture, financial services, utilities, manufacturing, and critical infrastructure. The transaction is expected to contribute approximately $3 million in annualized revenue and approximately $1.5 million in EBITDA for fiscal year 2026. Strategic SynergiesSecuvant’s expertise in...